Read Larry Connors' blog – Short Term Trading Strategies
"During the second quarter, we focused on winding down our research and development activities and satisfying outstanding financial obligations, as can be seen in the significant reduction in net loss during the quarter," stated Andrew Sauter, Avigen's Chief Executive Officer, President and Chief Financial Officer.
Financial Results
Avigen reported a net loss of $1.3 million, or $0.04 per share, for the quarter ended June 30, 2009, compared to $7.3 million, or $0.25 per share, for the quarter ended June 30, 2008. For the six months ended June 30, 2009 and 2008, Avigen reported a net loss of $8.5 million, or $0.29 per share, and $14.8 million, or $0.50 per share, respectively.
During the six months ended June 30, 2009, Avigen's Board of Directors and management have focused on reducing costs and preserving the value of the company's assets. On March 26, 2009, the Board of Directors announced that it intended to develop a plan that would maximize the liquidation value of the company.
Second Quarter Results
Research and development expenses for the three-month periods ended June 30, 2009 and 2008 were $562,000 and $5.9 million, respectively. This decrease reflects the wind down of most of Avigen's research and development activities and savings from the corporate restructuring initiated in November 2008. The company continues to support the ongoing clinical trial of AV411 that is funded by the National Institute on Drug Abuse (NIDA) for the treatment of opioid withdrawal.
General and administrative expenses for the three-month periods ended June 30, 2009 and 2008 were $1.4 million and $2.3 million, respectively. Approximately half of the expenses for the 2009 period represent costs for Avigen's remaining building lease, which is partially offset by sublease income.
Sublease income rose to $224,000 for the second quarter of 2009, reflecting the impact of entering into a new sublease agreement effective March 1, 2009.
Net interest income and other income were $347,000 and $703,000 for the quarters ended June 30, 2009 and 2008, respectively. This decrease primarily reflects the lower outstanding balances of interest-bearing cash and securities, as well as a general decline in market interest rates that have led to a lower average yield earned on Avigen's portfolio.
Six-Month Results
Research and development expenses for the six months ended June 30, 2009 and 2008 were $3.3 million and $12.2 million, respectively. This decrease reflects the wind down of most of Avigen's research and development activities and savings from the corporate restructuring initiated in November 2008.
General and administrative expenses for the six months ended June 30, 2009 and 2008 were $6.4 million and $4.6 million, respectively. The expenses for the 2009 period include a one-time severance charge of approximately $1.6 million in connection with the staff reduction announced during the first quarter, and approximately $2.1 million in legal and other professional services expenses, primarily in connection with Avigen's response to a proxy fight and unsolicited tender offer during the first quarter, as well as support for Avigen's review of strategic merger and acquisition opportunities.
Sublease income was $362,000 for the six months ended June 30, 2009 compared to $173,000 for the same period in 2008.
Net interest income and other expenses were $771,000 for the six months ended June 30, 2009 compared to $1.5 million for the same period in 2008.
About Avigen
Avigen is a biopharmaceutical company that has focused on identifying and developing differentiated products to treat patients with serious neurological and other disorders. For more information about Avigen, consult the company's website at www.avigen.com.
The Avigen, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2981
AVIGEN, INC.
SELECTED FINANCIAL INFORMATION
STATEMENTS OF OPERATIONS
(In thousands, except shares
and per share information)
(unaudited)
Three months ended Six months ended
June 30 June 30
------------------------ ------------------------
2009 2008 2009 2008
----------- ----------- ----------- -----------
Revenue $ 100 $ -- $ 100 $ --
Operating
expenses
Research and
development 562 5,901 3,340 12,163
General and
administrative 1,436 2,261 6,414 4,550
Impairment loss
related to
long-lived
assets -- -- -- (274)
----------- ----------- ----------- -----------
Total operating
expenses 1,998 8,162 9,754 16,439
Loss from
operations (1,898) (8,162) (9,654) (16,439)
Sublease income 224 118 362 173
Net interest
income and
other expense 347 703 771 1,514
----------- ----------- ----------- -----------
Net loss $ (1,327) $ (7,341) $ (8,521) $ (14,752)
=========== =========== =========== ===========
Basic and diluted
net loss per
common share $ (0.04) $ (0.25) $ (0.29) $ (0.50)
=========== =========== =========== ===========
Shares used in
basic and
diluted net loss
per common share
calculation 29,820,895 29,769,115 29,795,148 29,762,148
=========== =========== =========== ===========
CONDENSED BALANCE SHEETS
June 30, Dec. 31,
2009 2008
----------- -----------
(In thousands) (unaudited) (1)
Cash, cash equivalents and
available-for-sale securities $ 36,243 $ 47,803
Restricted investments - current $ 3,392 $ 7,036
Accrued interest and other current assets $ 548 $ 914
----------- -----------
Total current assets $ 40,183 $ 55,753
Restricted investments $ 2,000 $ 2,000
Property and equipment, net $ 33 $ 52
Deposits and other assets $ 217 $ 241
----------- -----------
Total assets $ 42,433 $ 58,046
=========== ===========
Current liabilities $ 2,555 $ 10,240
Long-term obligations $ 525 $ 602
Stockholders' equity $ 39,353 $ 47,204
----------- -----------
Total liabilities and stockholders' equity $ 42,433 $ 58,046
=========== ===========
(1) Derived from audited financial statements.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Avigen, Inc.
Avigen, Inc. Andrew Sauter,Chief Executive Officer, President and Chief Financial Officer 510-748-7172 Fax: 510-748-7155 ir@avigen.com 1301 Harbor Bay Parkway, Alameda, CA 94502
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.